FIRST ISOLATED IN 1990, interleukin-11 (IL-11) has proven to be a fascinating cytokine with pleiotropic effects on multiple tissues. Initially characterized as a hematopoietic cytokine with thrombopoietic activity, IL-11 has now been shown to be expressed and have activity in multiple other tissues, including brain, spinal cord neurons, gut, and testis. Yet to date, the physiologic role of this protein remains unknown. Our laboratory has recently generated a mutated allele of IL-11 in the mouse germline (X.D. and D.A.W., unpublished results, January 1997) and future studies of homozygous IL-11–deficient mice derived from these founder animals should illuminate the function(s) of this protein in vivo. In this article, we update current understanding of the biology of IL-11, concentrating on data published after the last comprehensive review published in 1994.1 

Human IL-11 was cloned in 1990 and details of this cloning and early work on IL-11 have been summarized previously.1 More recently the murine IL-11 cDNA was cloned using an expression library generated from a lipopolysaccharide (LPS)-induced murine fetal thymic cell line (T2).2 The murine IL-11 cDNA shares 80% homology with human IL-11 at the nucleotide level.2 Both human and murine IL-11 genomic sequences consist of 5 exons and 4 introns and have been mapped to chromosome 19 at band 19q13.3-q13.4 and to the centromeric region of chromosome 7, respectively2,3 (and M. McAndrew-Hill and D.A.W., unpublished results, June 1996). The 5′-flanking region of the human IL-11 gene contains several DNA motifs postulated to be involved in transcriptional control. A “TATA” box-like sequence, TATATAA, is located 180 nucleotides upstream from the translation initiation codon ATG.3 A 10-bp promoter sequence (5′ GGTGAGTCAG 3′) in this region contains an activator protein-1 (AP-1) site (underlined). JunD/AP-1 complexes are responsible for the basal-level transcription of IL-11 gene in bone marrow (BM) fibroblast cells.4 There are two polyadenylation sites located in the 3′ untranslated region (UTR) at nucleotide positions 6762 and 5591 and these alternative sites give rise to the 2.5- and 1.5-kb IL-11 mRNA transcripts expressed in several IL-1α–induced cell lines.3 5 

IL-11 precursor protein consists of 199 amino acids (aa), including a 21-aa leader sequence. The theoretical molecular weights of recombinant human (rh) and murine IL-11 are 19,144 daltons6 and 19,154 daltons,2 respectively. Mature human and primate IL-11 protein share 94% identity whereas human and murine proteins share 88% identity in the amino acid sequence.2,6,7 Although IL-11 is rich in proline residues (12%) and lacks cysteine residues (ie, lacks potential disulfide bonds), hIL-11 is highly helical (57% ± 1%) and is thermally stable (melting temperature [Tm] = 90°C).8 According to the structural model proposed by Czupryn et al,8 IL-11 contains a four-helix bundle topology (denoted A-D) whereby methionine residue 58 (Met58 ) and lysines (Lys41 and Lys98 ) are located on the surface of the protein. Chemical modifications (alkylation or site-directed mutagenesis) of the Met58 residue results in a 25-fold decrease in in vitro bioactivity of rhIL-11. Chemical modification of the Lys41 and Lys98 results in a 3-fold decrease in bioactivity. rhIL-11 lacking the four carboxyl-terminal residues has a 25-fold lower bioactivity and elimination of 8 or more carboxyl-terminal residues completely abolishes activity.9 The C-terminus of rhIL-11 is predicted to be helical and to be involved in the primary receptor binding site (site I). Important residues contributing to receptor binding in this site include Arg150, His153, Asp164, Trp165, and Arg168.8 Met58 is potentially involved in the receptor binding. In the region between Pro13 and Lys41, there are a number of residues (including Pro13, Glu16, Leu17, Leu22, Arg25, Leu28, Thr31, Arg32, Leu34, and Arg39 ) that are critical for the bioactivity of IL-11 and may constitute part of a gp130 binding site (site II).8 Lys41 and Lys98, as well as positively charged arginine residues, which are found on the exposed face of helix C, may also be involved in receptor binding site II.9 

IL-11 is expressed in vivo in a wide range of normal adult murine tissues (including hematopoietic tissues) as detected by reverse transcriptase-polymerase chain reaction (RT-PCR).10 IL-11 is detected by in situ hybridization in neurons of the central nervous system (CNS) and in developing spermatogonia of testis, where expression is developmentally regulated.10 As summarized in Table 1, IL-11 gene expression is observed in a variety of cells of mesenchymal origin. Expression in these cells can be modulated by several inflammatory cytokines and agonists as well as hormones, either alone or synergistically. Signaling pathways involved in induction of IL-11 expression vary between different cell types. For instance, IL-11 gene expression induced by IL-1α and phorbol myristate acetate (PMA) in PU-34 cells is regulated mostly at the posttranscriptional level by increased IL-11 mRNA stabilization. IL-1α–induced IL-11 mRNA stabilization in these cells is effected through a tyrosine kinase pathway, whereas PMA-induced IL-11 mRNA stabilization is dependent on H7-sensitive serine/threonine kinases and protein kinase C (PKC) pathways. There are multiple regions (eg, 5′UTR, coding region, and 3′UTR) within the IL-11 mRNA involved in IL-1α– and PMA-induced IL-11 mRNA stabilization. In addition, the presence of ATTTA motifs in the 3′-UTR of IL-11 mRNA may function as an RNA destabilizing sequence.4,11 Heparin, one of the extracellular matrix components that can trans-repress AP-1–mediated gene transcription, can also destabilize IL-11 mRNA after both IL-1α and PMA induction in PU-34 cells through competition for mRNA binding proteins.12 PKC-mediated signaling events may also be involved in the induction of IL-11 in connective tissues and osteosarcoma cell lines.13,14 Induction of IL-11 mRNA in these cells by the protein synthesis inhibitor, cyclohexamide, suggests that transcription of IL-11 is negatively regulated by protein(s) with short half-lives.14 In contrast to BM fibroblast cells, stimulation of IL-11 gene expression by IL-1α, transforming growth factor-β1 (TGF-β1) and TGF-β2 in respiratory epithelial and fibroblast cells is likely to be transcriptionally regulated15,16 via a pathway that is largely calmodulin-dependent and PKC-independent.16 In addition, increased intracellular calcium and inhibition of Na+/H+ pump activity can induce IL-11 mRNA accumulation in lung fibroblast cells. The synergistic effect of histamine and TGF-β1 in induction of IL-11 in human lung fibroblasts is, to a great extent, transcriptionally regulated and dependent on H1 receptors and a calcium/calmodulin-dependent activation pathway.17 Thus, regulation of IL-11 expression is complex and cell/tissue specific.

Table 1.

Tissue/Cell Types Expressing IL-11

TissueCell Type/Cell LinesInducers
CNS Hippocampal neurons (H19-7)10  IL-1α 
 Spinal motor and sympathetic neurons10  
 Astrocytic glioblastoma (U373, U87)163  IL-1β, PMA, calcium inophore 
Thymus Myeloid? (T2)2  LPS 
Lung Fibroblast (MRC5, CCL202)16  IL-1α, TGF-β1-2, PMA, RSV, Ca++/calmodulin 
 Epithelial (9HTE, A549)15 17  Rhinovirus, parainfluenza type 3, histamine (H1
 Muscle cells IL-1α, TGF-β1 
Bone Fibroblast (P-34, KM102)5-7 71  IL-1α, PMA, PKC 
 Osteosarcoma cell lines13 32  IL-1α, TGF-β1, PTH, PTHrP, cAMP, PKC 
 Osteoblast86  IL-1α, TGF-β1, TNF-α, PGE2, PTH, 1α, 25(OH)2D3 
Connective tissues Chondrocyte, synoviocyte14  IL-1β, TGF-β1, PMA, PKC 
 Vein endothelial cells32  IL-1α, TGF-β1,2, PMA 
Uterus Fibroblast IL-1α, PTHrP 
 Trophoblast (TPA30-1)5  IL-1α, PMA 
 Endometriotic & endometrial tissues164 165  
Skin Keratinocyte166  
 Melanoma cell lines167  
 Sarcoidosis (multinucleated giant cells)166  
Testis Round spermatids10  
TissueCell Type/Cell LinesInducers
CNS Hippocampal neurons (H19-7)10  IL-1α 
 Spinal motor and sympathetic neurons10  
 Astrocytic glioblastoma (U373, U87)163  IL-1β, PMA, calcium inophore 
Thymus Myeloid? (T2)2  LPS 
Lung Fibroblast (MRC5, CCL202)16  IL-1α, TGF-β1-2, PMA, RSV, Ca++/calmodulin 
 Epithelial (9HTE, A549)15 17  Rhinovirus, parainfluenza type 3, histamine (H1
 Muscle cells IL-1α, TGF-β1 
Bone Fibroblast (P-34, KM102)5-7 71  IL-1α, PMA, PKC 
 Osteosarcoma cell lines13 32  IL-1α, TGF-β1, PTH, PTHrP, cAMP, PKC 
 Osteoblast86  IL-1α, TGF-β1, TNF-α, PGE2, PTH, 1α, 25(OH)2D3 
Connective tissues Chondrocyte, synoviocyte14  IL-1β, TGF-β1, PMA, PKC 
 Vein endothelial cells32  IL-1α, TGF-β1,2, PMA 
Uterus Fibroblast IL-1α, PTHrP 
 Trophoblast (TPA30-1)5  IL-1α, PMA 
 Endometriotic & endometrial tissues164 165  
Skin Keratinocyte166  
 Melanoma cell lines167  
 Sarcoidosis (multinucleated giant cells)166  
Testis Round spermatids10  

Progenitor cells.IL-11 acts synergistically with other early and late acting growth factors to stimulate various stages and lineages of hematopoiesis. In synergy with IL-3,18-20 IL-4,19-22 IL-7, IL-12,23-25 IL-13,26 stem cell factor (SCF ),27 flt3 ligand,28 and granulocyte-macrophage colony-stimulating factor (GM-CSF ),27 IL-11 stimulates the proliferation of primitive stem cells, multipotential and committed progenitor cells from various sources including cord blood,29,30 BM,1,30-33 and peripheral blood34 in different culture systems.18-20,35 This proliferation appears to be due to the entry of a quiescent (G0 ) population of these cells into active cell cycle18 as well as shortening of the cell-cycle time in some cells.36 In combination with other cytokines present in hematopoietic microenvironment, IL-11 may increase commitment of primitive stem cells into the multilineage progenitor compartment and stimulate proliferation and differentiation of committed progenitor cells.37 This observation is consistent with published data showing that ex vivo expansion of murine BM cells with the cytokines IL-3, IL-6, IL-11, and SCF is associated with impaired engraftment of expanded cells in both normal and irradiated host.38,39 However, ex vivo expansion of BM cells using IL-11 and SCF can enhance short-term engraftment potential and such expanded cells have been shown to sustain hematopoiesis during serial transplants in lethally irradiated mice.40 In addition, chronic expression of IL-11 in hematopoietic cells via retroviral-mediated gene transfer appears to be associated with maintenance of a primitive population of cells after serial transplantation.41 The contradictory results from these studies may be due to different cytokine combinations or concentrations used in expansion of BM cells in vitro. Although in vivo IL-11 increases the cycling rates and absolute number of myeloid progenitors in both BM and spleen of normal mice,42 it has no effects on peripheral leukocyte counts when administered to normal rodents43,44 and nonhuman primates.45 

Megakaryocytopoiesis and thrombocytopoiesis.IL-11 acts synergistically with IL-3, thrombopoietin (TPO) (also termed megakaryocyte growth and development factor [MGDF ]),46,47 or SCF48 to stimulate various stages of megakaryocytopoiesis and thrombopoiesis in both murine49,50 and human51-53 BM cells. In vivo treatment with IL-11 results in marked stimulation of megakaryocytopoiesis in rodents, nonhuman primates,43-45,54 and humans55,56 (see also below), including the production, differentiation, and maturation of megakaryocytes. In the presence of soluble c-Mpl (the receptor for TPO), megakaryocyte colony formation and acetylcholinesterease (AchE) activities induced by IL-11 alone or in combination with IL-3 or SCF are reduced.48 Anti-TPO antiserum can also reduce IL-11–stimulated megakarocyte colony formation by 90%, whereas anti–IL-3 antiserum effects a 28% reduction in colony formation.57 These studies suggest that IL-11 effects on megakaryocytopoiesis and thrombopoiesis may be mediated in part via TPO. Recently, Weich et al57a have shown that IL-11α chain mRNA was detected in purified human CD41a(+), CD14(−) megakaryocyte precursors. Further, incubation of purified cells with rhIL-11 led to rapid phosphorylation of the gp130 subunit of the IL-11 receptor, indicating direct activation of the receptor signaling subunit by IL-11. IL-11 and TPO can also synergistically stimulate the proliferation of dormant multilineage progenitors by shortening Go , and this effect can be completely abrogated by addition of ACK2, a neutralizing antibody to c-kit, the receptor of SCF,58 suggesting that the synergistic effects of IL-11 and TPO on multilineage cells may be mediated in part by SCF/c-kit interactions.

Erythropoiesis.IL-11 alone or in combination with other cytokines (IL-3, SCF, or erythropoietin [Epo]) can stimulate multiple stages of erythropoiesis using murine and human BM cells and fetal liver cells as targets.1,32,59 The in vitro effect of IL-11 on burst-forming unit-erythroid (BFU-E) formation cannot be abrogated by antibodies against SCF, IL-3, or granulocyte-macrophage CSF (GM-CSF ), suggesting a direct effect of IL-11 on human and murine erythroid progenitors.60 In vivo studies of cytokine administration indicate that IL-11 and SCF may increase the input from a multilineage cell compartment into the erythroid lineage, whereas IL-11 and Epo may stimulate further amplification of erythroid cells. Moreover, IL-11 and SCF may lead to a redistribution of erythroid cells from BM to spleen.61 

Myelopoiesis.IL-11 also modulates the differentiation and maturation of myeloid progenitor cells. IL-11 in combination with SCF stimulates myeloid colony formation from murine Lin/Sca 1+ BM cells. These colonies are composed mostly of granulocytes and myeloid blasts. The combination of IL-11 with IL-13 or IL-4 can reduce the proportion of granulocytes and blasts in myeloid colonies, with a concomitant increase in macrophages.26 Combination treatment with IL-11, SCF, and G-CSF in the newborn rat has been shown to significantly increase peripheral neutrophil counts.62 63 

Lymphopoiesis.IL-11 in combination with SCF or IL-4 effectively supports the generation of B cells in primary cultures of BM cells from 5-fluorouracil (5-FU)–treated mice.23,64,65 Similar effects have been seen with flt3/flk-2 ligand66 using unfractionated murine fetal liver cells and with SCF and IL-7 in fractionated cells.67 IL-11 and IL-4 can also reverse the inhibitory effect of IL-3 on early B-lymphocyte development.68 The promotion of B-cell differentiation may be mediated by T cells.5,69 70 

Effects on hematopoietic microenvironment.IL-11 was originally isolated from cells derived from the hematopoietic microenvironment (HM)5-7,71,72 and may act as a paracrine or autocrine growth factor in this environment. Addition of IL-11 to human long-term BM culture (LTBMC) significantly increases the cellularity of the adherent cells, inhibits adipose accumulation in adherent cells, and leads to enhanced hematopoiesis.73 Addition of IL-11 and SCF to bone marrow cultures derived from aplastic anemia patients significantly enhances the formation of an adherent stromal layer,74 suggesting that IL-11 may have therapeutic value in aplastic anemia patients with defects in the HM. BM fibroblast growth can also be stimulated by the presence of megakaryocytes and the evolution of myelofibrosis is often linked with abnormal megakaryocytopoiesis. IL-11 has been shown to modulate megakaryocyte-dependent BM fibroblast stimulation.75,76 IL-11 with other cytokines has been shown to mobilize primitive hematopoietic stem/progenitor cells both in vitro37 and in vivo.77 Treatment with IL-11 and SCF can enhance mobilization of long-term repopulating cells from the BM to the spleen and from the BM to the blood of splenectomized mice.77 

Effects of IL-11 on epithelial cells.As mentioned above, alveolar and bronchial epithelial cells produce large amounts of IL-11. The upregulation of IL-11 production by inflammatory cytokines, respiratory syncytial virus (RSV), and retinoic acid (RA) suggests that IL-11 may play an important role in pulmonary inflammation.15 IL-11 and IL-11Rα are also expressed in epithelial cells of the gastrointestinal (GI) tract.78,79 In vitro studies show that IL-11 can directly interact with GI epithelial cells and reversibly inhibit proliferation of the intestinal crypt stem cell lines (IEC-6 and IEC-18).80,81 Thus, IL-11 may be involved in the normal growth control of GI epithelial cells. IL-11–induced decrease in proliferation of these cells may due to prolongation of the G1-S phase transition which is also associated with accumulation of the hypophosphorylated form of the retinoblastoma susceptibility gene product (pRB).81 In addition, IL-11 has been found to enhance GI absorption of iron in rats, which does not appear to be related to changes in erythropoiesis.82 

Osteoclastogenesis.IL-11 in combination with 1α,25-dihydroxyvitamin D 3 [1α,25(OH)2 D3 ] and parathyroid hormone (PTH) has been shown to stimulate osteoclast development and inhibit bone nodule formation in BM cultures and cocultures of BM with calvaria cells.83,84 Osteoblasts are important regulators of osteoclast-mediated bone resorption. The requirement of the presence of stromal/osteoblastic cells in IL-11–induced osteoclast development suggests that the effect of IL-11 may be mediated through the stimulation of other factors derived from stromal/osteoblastic cells.85 The osteoblast-dependent bone-resorptive activity of IL-11 can be inhibited by the calcitonin and cyclo-oxygenase inhibitor, indomethacin. Neutralizing antibody to IL-11 can partially negate the bone resorptive effects of PTH and block IL-1, tumor necrosis factor (TNF ), and 1α,25(OH)2D3 -induced osteoclast development.83 IL-11 can be induced in both human and murine primary osteoblasts as well as osteoblast-like osteosarcoma cell lines (Table 1).13 Primary osteoblasts express both IL-11Rα and gp130 mRNA, and gp130 mRNA can be upregulated by IL-1, PTH, and 1α,25(OH)2D3 .86 Mature osteoclasts also express IL-11Rα mRNA. These studies suggest that IL-11 is an important osteoblast-derived paracrine regulator of bone metabolism and that both bone-forming and bone-resorbing cells are potential targets of IL-11 action.86 

Neurogenesis.Du et al10 recently showed that IL-11 mRNA is expressed in hippocampal neuronal cells and in motor and sympathetic neurons of the spinal cord. Exogenous IL-11 stimulates the proliferation of hippocampal neuronal progenitor cells (H19-7) in a dose-dependent fashion.10 In addition, it has been previously shown that IL-11 and several other hematopoietic growth factors are survival and/or differentiation factors for murine fetal hippocampal neuronal progenitors (MK31).87 The production of IL-11 by alveolar and bronchial epithelial cells15 may further suggest that IL-11 is an important survival factor for sensory and motor neurons because the subepithelial space of lung is rich in nervous innervation and IL-11 stimulates production of substance P from sympathetic neurons.88 Previous investigators have speculated that mechanisms regulating the proliferation and differentiation of neural and hematopoietic cells may be similar.89-94 

Other effects.IL-11 has also been shown to have other nonhematopoietic activities1,32 such as stimulation of acute phase reactants both in vitro95,96 and in vivo,55 inhibition of adipogenesis,6,73,97 induction of a febrile response,98 and modulation of extra cellular matrix (ECM) metabolism,14 which may have a protective effect on connective tissues or could be involved in the pathogenesis of liver fibrosis and cirrhosis.99 In several in vitro cell culture systems, IL-11 appears to reduce pro-inflammatory cytokine expression, particularly the release of tumor necrosis factor-α (TNF-α) by monocytes/macrophages.99a 99b 

IL-11, like IL-6, oncostatin M (OSM), leukemia inhibitory factor (LIF ), and ciliary neurotrophic factor (CNTF ), uses the gp130 receptor common subunit for receptor function (Fig 1).100 Hilton et al101 have cloned the murine IL-11 receptor α-chain (IL-11Rα) by using a degenerate oligonucleotide probe corresponding to the conserved 5-aa motif Trp-Ser-Xaa-Trp-Ser (WSXWS) in the hematopoietin receptor family. The extracellular region of IL-11Rα shares sequence similarity to the α-chains of IL-6 and CNTF receptors (24% and 22% aa identity, respectively). The human IL-11Rα cDNA isolated by Nandurkar et al102 predicts a 422-aa protein and shares 85% and 84% nucleotide and aa identity with the murine IL-11Rα. The extracellular region of human IL-11Rα contains a hematopoietin domain with conserved cysteine residues and the WSXWS motif. The residue ‘X’ differs between the human and murine receptors. There are two isoforms of human IL-11 receptor α-chain which differ in the cytoplasmic domain. One isoform of human IL-11 receptor, similar to the human IL-6 and murine IL-11 receptors, has a short cytoplasmic domain (IL-11Rα1). The other isoform, similar to the human CNTF receptor, lacks this domain (IL-11Rα2). The functional significance of differences between the two isoforms are not known yet. IL-6, CNTF, and IL-11 receptor α-chains overall share 32% identity among extracellular domains and are also structurally related. There is 42% identity between the C-terminal cytokine-receptor–like domains of IL-11Rα1 and CNTFRα.103 The genomic structure of hIL-11Rα1 consists of 12 exons and 12 introns within a 9-kb genomic region. Human IL-11Rα gene is located on chromosome 9 band 9p13, where the CNTFR gene is also located.104 Robb et al105 have recently reported the structure of the murine IL-11Rα gene, which contains 14 exons. Evidence suggests the use of alternative first exons in a developmentally regulated fashion.105 A second murine IL-11Rα–like locus (IL-11Rα2) has been reported with sequence homology to exons 2-13 of IL-11Rα1.105 This locus appears to be present in only some strains of mice.

Fig. 1.

Possible signaling pathways mediated by IL-11.

Fig. 1.

Possible signaling pathways mediated by IL-11.

Close modal

Binding of IL-11 ligand to either human or murine IL-11Rα occurs at low affinity and, although necessary, is not sufficient for signal transduction. The generation of a high-affinity IL-11 receptor capable of generating a biologic signal requires coexpression of the IL-11Rα and gp130.101,102 IL-11Rα mRNA is detectable in several murine cell lines, including 3T3-L1 cells, BAd stromal cells, the embryonic carcinoma cell line PC13, and factor-dependent hematopoietic cell lines FDCP-1 and D35. A wide range of primary tissues express IL-11Rα mRNA, including hematopoietic tissues (BM, spleen, and thymus), liver, brain, heart, kidney, muscle, and salivary gland as well as cells of the GI tract.78,101,105 Human IL-11 receptor mRNA is expressed in myeloid (K562), megakaryocytic (Mo7E), and erythroid (TF1) leukemia cell lines as well as osteosarcoma cell lines (MG-63 and Saos-2).103 

As mentioned above, gp130 is the common subunit of the IL-6, OSM, LIF, and CNTF as well as IL-11 receptors.106-109 Binding of IL-11 to specific cell-surface IL-11Rα receptor induces heterodimerization, tyrosine phosphorylation,110,111 and activation of gp130.106,108,112 The activated IL-11 receptor⋅gp130 complex probably activates tyrosine kinases of the Janus kinase (Jak) family (Fig 1).113,114 IL-11 has also been shown to promote the formation of the active GTP-bound form of Ras115 and induce the tyrosine phosphorylation and activation of mitogen-activated protein kinase (MAPK),116 a key downstream signaling target of Ras. After activation of IL-11 receptor by IL-11 binding, Jak2 forms a complex with the adapter protein, growth factor receptor binding protein 2 (Grb2), and gp130, thus bringing SOS (Son Of Sevenless) to the plasma membrane where Ras is located, hence activating Ras and initiating the Ras signaling pathway.115 In addition to use of gp130 as a common subunit in signal transduction, the association of Jak and Ras signaling pathways on stimulation with IL-11 and similar cytokines is another unique feature of this family of cytokines. IL-11 and other cytokines using gp130 as a signal transducer can trigger the activation of MAPKs and the 85- 92-kD ribosomal protein S6 kinase (pp90rsk), which is followed by activation of a set of common primary response genes (Egr-l or TIS 8, TTP or TIS 11,Jun B and 3CH134, which encodes a phosphatase which can inactivate MAPKs).116,117 Src-family protein tyrosine kinases, including Fyn, Yes, and Src, may also play an important role in IL-11 signaling. Jak2 and Fyn are transiently associated with Grb2 upon stimulation with IL-11,115 suggesting that IL-11–induced signaling in the Ras/MAPK pathway is partly through Fyn. Stimulation of 3T3-L1 cells with IL-11 results in a threefold increase in tyrosine phosphorylation of p62yes and a 15-fold increase in phosphorylation of p60Src.118 

In addition to MAPK phosphatase (3CH134), the ubiquitous tyrosine phosphatase Syp also associates with gp130 and Jak2 in response to IL-11 stimulation.119 Herbimycin A, which is a tyrosine kinase inhibitor, can block the activation of MAPK and pp90rsk induced by IL-11.116 A serine/threonine kinase inhibitor H7, which may act on signaling pathways downstream of pp90rsk, can inhibit pp90rsk activity, suggesting H7-sensitive kinases are crucial in IL-11 signaling.116,117 Lipid second messengers are also involved in IL-11 signal transduction. IL-11 treatment in 3T3-L1 cells activates phospholipase D to produce phosphatidic acid (PA). Increased levels of PA enhance tyrosine phosphorylation of MAPKs and transduce some signals in this cell line.120 IL-11–induced phosphorylation of tyrosine kinases and H7sensitive kinases are PKC-independent and cAMP-, cGMP-, and calcium/calmodulin-independent.110,112 IL-11 and other cytokines sharing the signal transducing subunit, gp130, can activate acute-phase response factor (APRF ) by tyrosine phosphorylation in variety of cell types. This transcriptional factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family, especially STAT91. STAT91 and related proteins were originally identified as interferon-activated transcriptional factors. This suggests a central role APRF in gp130-mediated signaling.121 IL-11 also stimulates tyrosine phosphorylation and nuclear translocation of STAT91 and a related 89-kD protein.117 The possible signaling pathways mediated by IL-11 are summarized in Fig 1.

Syngeneic BM transplant (BMT) models.Administration of IL-11 accelerates recovery of megakaryopoiesis and myelopoiesis in BMT mice (Table 2).122 Enhanced recovery of these lineages is associated with significantly decreased mortality and morbidity from lethal exogenous infection with Pseudomonas aeruginosa and decreased mouse-tail bleeding time.123 BMT recipient mice treated with the combination of IL-11 and SCF show shortened periods of cytopenia in all myeloid lineages.124 Lethally irradiated mice transplanted with syngeneic BM cells infected with a retrovirus expressing the human IL-11 cDNA demonstrate similar hematological changes as seen in BMT recipient mice treated with rhIL-11 until day 28 post BMT.125 However, in one such study, while elevated peripheral platelet counts were sustained chronically, no changes in peripheral erythrocyte or leukocyte counts were observed long term despite a greater than 20-fold increase in splenic myeloid progenitor content. Two of 20 secondary recipients of BM cells transduced with a retrovirus expressing hIL-11 cDNA developed myeloid leukemia. All mice showed systemic effects of chronic IL-11 exposure (Table 2).126,127 A recent study has shown that ectopic expression of murine IL-11 via a retrovirus vector accelerated recovery of platelets and leukocytes (neutrophils) in secondary and tertiary BMT mice. This study also suggests that IL-11 expression in vivo may enhance maintenance of primitive hematopoietic stem cells.41 

Table 2.

Effects of IL-11 on Cytoablative Preclinical Models

ModelsPeripheral BloodBone MarrowSpleenThymusGI TractOther
BMT122-127 WBC↑, N↑ CFU-mix↑ CFU-mix   Myeloid leukemia 
 Plt↑ CFU-GM↑ CFU-GM↑   Body weight↓ 
 Reticulocyte↑ CFU-MK↑ CFU-MK↑   Hyperactive state 
 Pseudomonas aeruginosa LD50↑ Cellularity↑ Cellularity↑   Thymic atrophy 
 Tail bleeding time↓     Inflammation 
      Acute-phase protein↑ 
Sublethal122 128  WBC↑  Cellularity↑ Cellularity↑  Pneumonitis 
 Plt↑  T- & B-cell function T- & B-cell function↑   
Chemotherapy42,66 129-133  WBC↑, N↑ Plt↑ Cellularity↑ tCellularity↑  ↓Frequency, severity and duration of oral mucositis ↑Survival 
 Hct↑ CFU-mix↑ SRBC-specific plaque    
 Pancytopenia↓ CFU-GM↑ Forming cells↑    
 SRBC-specific Ab↑ BFU-E↑ CFU-mix, GM, BFU-E↑    
Chemoradiation therapy79 134  Late recovery of Plt & Hct BFU-E↑ BFU-E, CFU-GM & CFU-MK↑ at day 15 postirradiation  ↑Mitotic index & PCNA+ cells in crypts ↑Recovery of spermatogenesis 
 Mild ↑Plt at early stage postirradiation CFU-GM↑   ↓Apoptosis ↑Survival 
  CFU-MK↑     
  at day 15 & 30 postirradiation     
ModelsPeripheral BloodBone MarrowSpleenThymusGI TractOther
BMT122-127 WBC↑, N↑ CFU-mix↑ CFU-mix   Myeloid leukemia 
 Plt↑ CFU-GM↑ CFU-GM↑   Body weight↓ 
 Reticulocyte↑ CFU-MK↑ CFU-MK↑   Hyperactive state 
 Pseudomonas aeruginosa LD50↑ Cellularity↑ Cellularity↑   Thymic atrophy 
 Tail bleeding time↓     Inflammation 
      Acute-phase protein↑ 
Sublethal122 128  WBC↑  Cellularity↑ Cellularity↑  Pneumonitis 
 Plt↑  T- & B-cell function T- & B-cell function↑   
Chemotherapy42,66 129-133  WBC↑, N↑ Plt↑ Cellularity↑ tCellularity↑  ↓Frequency, severity and duration of oral mucositis ↑Survival 
 Hct↑ CFU-mix↑ SRBC-specific plaque    
 Pancytopenia↓ CFU-GM↑ Forming cells↑    
 SRBC-specific Ab↑ BFU-E↑ CFU-mix, GM, BFU-E↑    
Chemoradiation therapy79 134  Late recovery of Plt & Hct BFU-E↑ BFU-E, CFU-GM & CFU-MK↑ at day 15 postirradiation  ↑Mitotic index & PCNA+ cells in crypts ↑Recovery of spermatogenesis 
 Mild ↑Plt at early stage postirradiation CFU-GM↑   ↓Apoptosis ↑Survival 
  CFU-MK↑     
  at day 15 & 30 postirradiation     

Abbreviations: CFU-mix, colony-forming unit-mix; CFU-GM, colony-forming unit-granulocyte/macrophage; CFU-MK, colony-forming unit-megakaryocyte; WBC, white blood cells; N, neutrophils; Plt, platelets; Hct, hematocrit; SRBC, sheep red blood cell; PCNA, proliferating cell nuclear antigen.

Sublethal radiation (non-BMT) models.In contrast to the effects in BMT models, IL-11 treatment has little effect on progenitor compartments in sublethally (600 cGy) irradiated mice.122 IL-11 treatment was shown to restore thymus and spleen cell numbers as well as T- and B-cell mitogen responsiveness in mice exposed to 200 cGy irradiation (Table 2). Sublethal irradiated dogs (200 cGy) treated with IL-11 show a modest trend toward faster platelet recovery. Some of the dogs in this study demonstrated pneumonitis, the etiology of which is unclear.128 

Chemotherapy models.Chemotherapy is often associated with blood cytopenias and immunosuppression as well as GI mucosal damage. IL-11 treatment significantly reduces chemotherapy related morbidity and mortality129-133 and is associated with accelerated recovery of both hematopoiesis42,132 and the immune response42,70 in different chemotherapy preclinical models (Table 2). Mortality associated with repeated doses of 5-FU is abrogated by pretreatment with IL-11 and SCF, but not by infusion with BM cells, suggesting that in this model IL-11 and SCF pretreatment may protect tissues other than hematopoietic tissues adversely affected by chemotherapy.129 In a hamster model of oral mucositis, IL-11 decreases the frequency, severity, and duration of oral mucositis in a dose-dependent fashion131,133 with little changes on BM cellularity, strengthening the suggestion that the protective mechanism of IL-11 on mucositis is due, at least in part, to effects on epithelial and/or connective tissues.133 

Combined chemo-/radiation therapy models.IL-11 administration markedly decreases morbidity and mortality due to sepsis by endogenous gut organisms79 and accelerates recovery of spermatogenesis10 in mice treated with combined chemo-/radiation therapy (5-FU and sublethal irradiation). The increased survival is associated with increased proliferation of crypt cells and decreased apoptosis of villous/crypt cells.134 The seemingly contradictory effects of IL-11 on GI crypt cell proliferation seen in in vitro78,80 and in vivo79 studies may be due to distinctly different effects on damaged versus undamaged cell populations: inhibition of proliferation before damage (seen in in vitro cell lines) and stimulation of proliferation post damage (seen in in vivo models of gut cell damage). This explanation is supported by the finding that pretreatment of mice with IL-11 followed by irradiation is associated with significant increases in the survival of intestinal crypt stem cells.135 In addition, recent studies show pretreatment of mice with IL-11 significantly reduces ischemia/reperfusion-induced small-bowel injury.136 The effect of IL-11 on combined chemo-/radiation therapy–induced gut mucosal damage may prove to be important in clinical use in cancer chemotherapy and BM transplant protocols in the future. The effects of IL-11 on cytoablative preclinical models are summarized in Table 2.

Other GI disease models.Acute colitis caused by chemical damage and chronic inflammatory bowel disease in transgenic animals expressing human HLA-B27 and β2-microglobulin are improved at both the gross and microscopic level by administration of IL-11.131 IL-11 treatment has proliferative effects on intestinal mucosa in mice after ischemic bowel necrosis,136 in a murine burn model,137 and in a rat short-bowel model.138 In all of these models, significantly increased survival rates are seen in mice treated with IL-11. IL-11 treatment also increases peripheral lymphocyte counts and decreases enteric bacterial translocation in both bowel ischemia and systemic burn models.

Sepsis models.Pretreatment with IL-11 significantly reduces mortality in a murine model of toxic shock syndrome139 and in experimental group B streptococcal (GBS) sepsis in neonatal rats.140 Endogenous IL-11 may play a role in the pathophysiologic response of neonatal animals to bacterial sepsis and associated thrombocytopenia.140 In a rabbit model of endotoxemia, IL-11 treatment prevents hypotension and decreases GI mucosal damage induced by lipopolysaccharide (LPS).141 The anti-inflammatory effects of IL-11 on both murine and rabbit models of endotoxemia appears to be due to inhibition of the production of proinflammatory mediators through effects on macrophages.142 

IL-11 acts as a synergistic factor with IL-3, GM-CSF, and SCF to stimulate proliferation of human primary leukemia cells, myeloid leukemia cell lines,143,144 megakaryoblastic cell lines,145 and erythroleukemic cell lines108 and to stimulate leukemic blast colony formation.143,144 IL-11 mRNA expression in leukemic cells and inhibition of leukemic cell growth by IL-11 antisense oligonucleotides suggest that IL-11 may function as an autocrine growth factor in leukemic cell lines.144,145 Although IL-11 stimulates the proliferation of murine plasmacytoma cells5,146 and murine hybridoma cells,147-149 the effect of IL-11 on the growth of human myeloma/plasmacytoma cells is controversial. IL-11 has no effect on the growth of freshly isolated human plasmacytoma cells.146,150 However, IL-11 can stimulate proliferation in two of eight human myeloma cell lines tested so far.146,151 As expected, anti-gp130 monoclonal antibodies can inhibit growth stimulation by IL-11 in human myeloma cell lines.152 The plasmacytoma growth inhibitor restrictin-P (also called activin A, follicle-stimulating hormone releasing protein, or erythroid differentiation factor), another growth regulatory protein derived from BM stromal, can inhibit the growth of IL-11–stimulated murine hybridoma cells.153 

IL-11 has now been evaluated in several human clinical trials. In the initial phase I trial, women with advanced-stage breast cancer undergoing high-dose chemotherapy were treated with increasing doses of IL-11 (up to 100 μg/kg/d) both before therapy and after each of four cycles of combined chemotherapy. IL-11 administration was associated with a dose-dependent trend toward increased platelet counts, and patients receiving rhIL-11 at doses >25 μg/kg/d showed attenuated postchemotherapy thrombocytopenia after the first and second cycles.55 Increased peripheral platelet counts were associate with both stimulation of platelet production and megakaryocyte maturation, as evidenced by increased numbers of BM colony-forming unit-megakaryocyte (CFU-MK), increased megakaryocyte numbers, and higher megakaryocyte ploidy.56 In contrast to effects seen in various preclinic studies, IL-11 treatment in this trial had no significant effect on leukopenia or neutropenia due to chemotherapy.55 However, IL-11 treatment was associated with increased BM cellularity, and increased numbers and cycling of immature erythroid and myeloid precusors.56 

IL-11 treatment in these patients was well tolerated at doses of 10 to 50 μg/kg/d. The most common side effect noted was a reversible anemia. The anemia was non–dose-related and decreases of ≈20% in hematocrits, possibly due to increased plasma volume, were seen.55,154 Other reversible side effects included arthralgias, myalgias, fatigue, nausea, headache, and edema. Unlike many other cytokines, IL-11 treatment was not associated with an increased incidence of fever. IL-11 administration increased the plasma concentrations of acute-phase reactants, including C-reactive protein, fibrinogen, and haptoglobin at all doses.55 

In several phase I/II trials, IL-11 has also been well tolerated in doses up to 50 μg/kg/d and appears to be a promising agent for accelerating hematopoietic recovery after multiple cancer therapies. The combined administration of IL-11 with G-CSF (5 μg/kg/d) in breast cancer patients receiving high-dose cyclophosphamide, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and thiotepa followed by autologous BMT effectively accelerates both peripheral neutrophil and platelet recoveries.155 In a phase I/II trial in children with solid tumors or lymphoma, IL-11 (50 μg/kg/d) and G-CSF (10 μg/kg/d) administration after ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appears to decrease the median number of platelet transfusions required (12 v 2), and reduces the days to recovery of both neutrophils (21 v 17.5 days) and platelets (27 v 22 days) when compared to ICE + G-CSF alone.156 Preliminary results from both trials cited above have not been reported in full at this point and it is not clear whether these differences are significant.

A multicenter, randomized, placebo-controlled IL-11 phase II clinical trial has been conducted in 93 cancer patients who had received at least one platelet transfusion during a prior chemotherapy cycle (secondary prophylaxis design). These patients were given an additional cycle of the same chemotherapy without dose reduction and were randomized to receive either rhIL-11 (at a dose of 25 or 50 μg/kg) or placebo. The patients treated with rhIL-11 in this phase II study were less likely to require platelet transfusions than the patients receiving placebo. For the patients treated with IL-11 at 25 μg/kg and 50 μg/kg, 30% (8 of 27) required no platelet transfusions compared to 1 of 27 patients treated with placebo. This difference was statistically significant (P < .05). The median number of platelet transfusions required among the groups treated with 50 μg/kg, 25 μg/kg, and placebo was 1, 2, and 3, respectively. The profile of side effects was similar to that seen in phase I studies. Most side effects were mild to moderate in severity and were reversible after IL-11 treatment was discontinued.157,158 Based on observations of the potent effects of IL-11 in models of gut damage, a major advantage of IL-11 may be the simultaneous effects of the cytokine on both BM and GI toxicities of chemotherapy and irradiation. A dose-escalating phase I/II randomized placebo-controlled human study examining the effects of IL-11 in patients with Crohn's disease has recently been completed.168 Based on the results of this trial, additional trials in Crohn's disease and in chemotherapy-induced mucositis are anticipated (Genetics Institute, personal communication, James Kaye, October 1996).

The recent cloning of the ligand for c-mpl159-162 provides another, and potentially very useful, therapeutic approach to thrombocytopenic states. Early trials with TPO (also termed MGDF ) appear promising and it will require multiple trials in various pathologic conditions to determine optimal cytokine combinations to enhance recovery of hematopoietic lineages with the least side effects. At the present time it would appear that IL-11 will be a useful thrombopoietin and may be uniquely useful in stimulating the recovery of the BM and the GI tract simultaneously after therapy-induced damage.

X.D. is supported by Grant-in-Aid No. 95-6, Riley Memorial Association. D.A.W. receives payments from Children's Hospital, Boston, MA, based on certain milestones set forth in an IL-11 agreement between Genetics Institute, Cambridge, MA, and Children's Hospital.

Address reprint requests to David A. Williams, MD, Herman B Wells Center for Pediatric Research, James Whitcomb Riley Hospital for Children, 702 Barnhill Dr, Room #2600, Indianapolis, IN 46202-5225.

1
Du XX
 
Williams DA
Interleukin-11: A multifunctional growth factor derived from the hematopoietic microenvironment.
Blood
83
1994
2030
2
Morris
 
JC
Neben
 
S
Bennett
 
F
Finnerty
 
H
Long
 
A
Beiert
 
DR
Kovacic
 
S
McCoy
 
JM
DiBlasio-Smith
 
E
LaVallie
 
ER
Caruso
 
A
Calvetti
 
J
Morris
 
G
Weich
 
N
Paul
 
SR
Crossier
 
PS
Turner
 
KJ
Wood
 
CR
Molecular cloning and characterization of murine interleukin-11.
Exp Hematol
24
1996
1369
3
McKinley
 
D
Wu
 
Q
Yang-Feng
 
T
Yang
 
Y-C
Genomic sequence and chromosomal location of human interleukin (IL)-11 gene.
Genomics
13
1992
814
4
Yang
 
L
Yang
 
Y-C
Regulation of interleukin (IL)-11 gene expression in IL-11 induced primate bone marrow stromal cells.
J Biol Chem
269
1994
32732
5
Paul
 
SR
Bennett
 
F
Calvetti
 
JA
Kelleher
 
K
Wood
 
CR
O'Hara
 
RM Jr
Leary
 
AC
Sibley
 
B
Clark
 
SC
Williams
 
DA
Yang
 
Y-C
Molecular cloning of a cDNA encoding interleukin 11, a novel stromal cell-derived lymphopoietic and hematopoietic cytokine.
Proc Natl Acad Sci USA
87
1990
7512
6
Ohsumi
 
J
Miyadai
 
I
Ishikawa-Ohsumi
 
H
Sakakibara
 
S
Mita-Honjo
 
K
Takiguchi
 
T
Adipogenesis inhibitory factor. A novel inhibitory regulator of adipose conversion in bone marrow.
FEBS Lett
288
1991
13
7
Kawashima
 
I
Ohsumi
 
J
Mita-Honjo
 
K
Shimoda-Takano
 
K
Ishikawa
 
H
Sakakibara
 
S
Miyadai
 
K
Takiguchi
 
Y
Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with interleukin-11.
FEBS Lett
283
1991
199
8
Czupryn
 
M
Bennett
 
F
Dube
 
J
Grant
 
K
Scobie
 
H
Sookdeo
 
H
McCoy
 
JM
Alanine-scanning mutagenesis of human interleukin-11: Identification of regions important for biological activity.
Ann NY Acad Sci
762
1995
152
9
Czupryn
 
MJ
McCoy
 
JM
Scoble
 
HA
Structure-function relationships in human interleukin-11.
J Biol Chem
270
1995
978
10
Du XX
 
Everett ET
Wang
 
G
Lee
 
W-H
Yang
 
Z
Williams
 
DA
Murine interleukin-11 (IL-11) is expressed at high levels in the hippocampus and expression is developmentally regulated in the testis.
J Cell Physiol
168
1996
362
11
Yang
 
L
Steussy
 
CN
Fuhrer
 
DK
Hamilton
 
J
Yang
 
Y-C
Interleukin-11 mRNA stabilization in phorbol ester-stimulated primate bone marrow stromal cells.
Mol Cell Biol
16
1996
3300
12
Yang
 
L
Yang
 
Y-C
Heparin inhibits the expression of interleukin-11 and granulocyte-macrophage colony-stimulating factor in primate bone marrow stromal fibroblasts through mRNA destabilization.
Blood
86
1995
2526
13
Elias
 
JA
Tang
 
W
Horowitz
 
MC
Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production.
Endocrinology
136
1995
489
14
Maier
 
R
Ganu
 
V
Lotz
 
M
Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases.
J Biol Chem
268
1993
21527
15
Elias
 
JA
Zheng
 
T
Einarsson
 
O
Landry
 
M
Trow
 
T
Rebert
 
N
Panuska
 
J
Epithelial interleukin-11: Regulation by cytokines, respiratory syncytial virus, and retinoic acid.
J Biol Chem
269
1994
22261
16
Elias
 
JA
Zheng
 
T
Whiting
 
NL
Trow
 
TK
Merrill
 
WW
Zitnik
 
R
Ray
 
P
Alderman
 
EM
IL-1 and transforming growth factor-β regulation of fibroblast-derived IL-11.
J Immunol
152
1994
2421
17
Zheng
 
T
Nathanson
 
MH
Elias
 
JA
Histamine augments cytoking-stimulated IL-11 production by human lung fibroblasts.
J Immunol
153
1994
4742
18
Leary
 
AG
Zeng
 
HQ
Clark
 
SC
Ogawa
 
M
Growth factor requirements for survival in Go and entry into the cell cycle of primitive human hemopoietic progenitors.
Proc Natl Acad Sci USA
89
1992
4013
19
Musashi
 
M
Yang
 
Y-C
Paul
 
SR
Clark
 
SC
Sudo
 
T
Ogawa
 
M
Direct and synergistic effects of interleukin 11 on murine hematopoiesis in culture.
Proc Natl Acad Sci USA
88
1991
765
20
Tsuji
 
K
Lyman
 
SD
Sudo
 
T
Clark
 
SC
Ogawa
 
M
Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit ), interleukin-11, and other early acting factors in culture.
Blood
79
1992
2855
21
Jacobsen
 
FW
Keller
 
JR
Ruscetti
 
FW
Veiby
 
OP
Jacobsen
 
SE
Direct synergistic effects of IL-4 and IL-11 on the proliferation of primitive hematopoietic progenitor cells.
Exp Hematol
23
1995
990
22
Musashi
 
M
Clark
 
SC
Sudo
 
T
Urdal
 
DL
Ogawa
 
M
Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice.
Blood
78
1991
1448
23
Hirayama
 
F
Katayama
 
N
Neben
 
S
Donaldson
 
D
Nickbarg
 
EB
Clark
 
SC
Ogawa
 
M
Synergistic interaction between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture.
Blood
83
1994
92
24
Ploemacher
 
RE
van Soest
 
PL
Boudewijn
 
A
Neben
 
S
Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 or steel factor.
Leukemia
7
1993
1374
25
Ploemacher
 
RE
van Soest
 
PL
Voorwinden
 
H
Boudewijn
 
A
Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hematopoietic stem cells in liquid culture.
Leukemia
7
1993
1381
26
Jacobsen
 
SEW
Okkenhaug
 
C
Veiby
 
OP
Caput
 
D
Ferrara
 
P
Minty
 
A
Interleukin 13: Novel role in direct regulation of proliferation and differentiation of primitive hematopoietic progenitor cells.
J Exp Med
180
1994
75
27
Lemoli
 
RM
Fogli
 
M
Fortuna
 
A
Motta
 
MR
Rizzi
 
S
Benini
 
C
Tura
 
S
Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33−DR− cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor.
Exp Hematol
21
1993
1668
28
Jacobsen
 
SE
Okkenhaug
 
C
Myklebust
 
J
Veiby
 
OP
Lyman
 
SD
The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interations with interleukin (IL) 11, IL-12, and other hematopoietic growth factors.
J Exp Med
181
1995
1357
29
Bertolini
 
F
Lazzari
 
L
Lauri
 
E
Corsini
 
C
Sirchia
 
G
Cord blood plasma-mediated ex vivo expansion of hematopoietic progenitor cells.
Bone Marrow Transplant
14
1994
347
30
van de Ven
 
C
Ishizawa
 
L
Law
 
P
Cairo
 
MS
IL-11 in combination with SLF and G-CSF or GM-CSF significantly increases expansion of isolated CD34+ cell population from cord blood versus adult bone marrow.
Exp Hematol
23
1995
1289
31
Ariyama
 
Y
Misawa
 
S
Sonoda
 
Y
Synergistic effects of stem cell factor and interleukin 6 or interleukin 11 on the expansion of murine hematopoietic progenitors in liquid suspension culture.
Stem Cells
13
1995
404
32
Du XX
 
Williams DA
Update on development of interleukin-11.
Curr Opin Hematol
2
1995
182
33
Neben
 
S
Donaldson
 
D
Sieff
 
C
Mauch
 
P
Bodine
 
D
Ferrara
 
J
Yetz-Aldape
 
J
Turner
 
K
Synergistic effects of interleukin-11 with other growth factors on the expansion murine hematopoietic progenitors and maintenance of stem cells in liquid culture.
Exp Hematol
22
1994
353
34
Sato
 
N
Sawada
 
K
Koizumi
 
K
Tarumi
 
T
Leko
 
M
Yasukouchi
 
T
Yamaguchi
 
M
Takahashi
 
TA
Sekiguchi
 
S
Koike
 
T
In vitro expansion of human peripheral blood CD34+ cells.
Blood
82
1993
3600
35
Schibler
 
KR
Yang
 
Y-C
Christensen
 
RD
Effect of interleukin-11 on cycling status and clonogenic maturation of fetal and adult hematopoietic protenitors.
Blood
80
1992
900
36
Tanaka
 
R
Katayama
 
N
Ohishi
 
K
Mahumd
 
N
Itoh
 
R
Tanaka
 
Y
Komada
 
Y
Minami
 
N
Sakurai
 
M
Shirakawa
 
S
Shiku
 
H
Accelerated cell-cycling of hematopoietic progenitor cells by growth factors.
Blood
86
1995
73
37
Du XX
 
Scott D
Yang
 
ZX
Cooper
 
R
Xiao
 
XL
Williams
 
DA
Interleukin-11 stimulates multilineage progenitors, but not stem cells, in murine and human long-term marrow cultures.
Blood
86
1995
128
38
Peters
 
SO
Kittler
 
EL
Ramshaw
 
HS
Quesenberry
 
PJ
Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts.
Blood
87
1996
30
39
Peters
 
SO
Kittler
 
ELW
Ramshaw
 
HS
Quesenberry
 
PJ
Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts.
Exp Hematol
23
1995
461
40
Holyoake
 
TL
Freshney
 
MG
McNair
 
L
Parker
 
A
N.
Steward
 
WP
Fitzsimons
 
E
Graham
 
GJ
Pragnell
 
IB
Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow.
Blood
87
1996
4589
41
Hawley
 
RG
Hawley
 
TS
Fong
 
AZC
Quinto
 
C
Collins
 
M
Leonard
 
JP
Goldman
 
SJ
Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin-11.
Proc Natl Acad Sci USA
93
1996
10297
42
Hangoc
 
G
Yin
 
T
Cooper
 
S
Schendel
 
P
Yang
 
Y-C
Broxmeyer
 
HE
In vivo effects of recombinant interleukin-11 on myelopoiesis in mice.
Blood
81
1993
965
43
Neben
 
TY
Loebelenz
 
J
Hayes
 
L
McCarthy
 
K
Stoudemire
 
J
Schaub
 
R
Goldman
 
SJ
Recombinant human interleukin-11 stimulates megakaryocytopoesis and increases peripheral platelets in normal and splenectomized mice.
Blood
81
1993
901
44
Yonemura
 
Y
Kawakita
 
M
Masuda
 
T
Fujimoto
 
K
Takasuki
 
K
Effect of recombinant human interleukin-11 on rat megakaryopoiesis and thrombopoiesis in vivo: Comparative study with interleukin-6.
Br J Haematol
84
1993
16
45
Mason L, Timony G, Perkin C, Badalone V, Bree A, Goldman S, Hayes L, Schaub R: Human recombinant interleukin-11 promotes maturation of bone marrow megakaryocytes in non-human primates: An electron microscopic study. Blood 82:69a, 1993 (abstr, suppl 1)
46
Broudy
 
VC
Lin
 
NL
Kaushansky
 
K
Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro.
Blood
85
1995
1719
47
Kaushansky
 
K
Lok
 
S
Holly
 
RD
Broudy
 
VC
Lin
 
N
Bailey
 
MC
Forstrom
 
JW
Buddle
 
MM
Oort
 
PJ
Hagen
 
FS
Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin.
Nature
369
1994
568
48
Kaushansky
 
K
Broudy
 
VC
Lin
 
N
Jorgensen
 
MJ
McCarty
 
J
Fox
 
N
Zucker-Franklin
 
D
Lofton-Day
 
C
Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development.
Proc Natl Acad Sci USA
92
1995
3234
49
Tsukada
 
J
Misago
 
M
Ogawa
 
R
Oda
 
S
Morimoto
 
I
Eto
 
S
Kikuchi
 
M
Synergism between serum factor(s) and erythropoietin in inducing murine megakaryocyte colony formation: The synergistic factor in serum is distinct from interleukin-11 and stem cell factor (c-kit ligand).
Blood
81
1993
866
50
Yonemura
 
Y
Kawakita
 
M
Masuda
 
T
Fujimoto
 
K
Kato
 
K
Takatsuki
 
K
Synergistic effects of interleukin 3 and interleukin 11 on murine megakaryopoiesis in serum-free culture.
Exp Hematol
20
1992
1011
51
Bruno
 
E
Briddell
 
RA
Cooper
 
RJ
Hoffman
 
R
Effects of recombinant interleukin-11 on human megakaryocyte progenitor cells.
Exp Hematol
19
1991
378
52
Burstein
 
SA
Mei
 
RL
Henthorn
 
J
Friese
 
P
Turner
 
K
Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro.
J Cell Physiol
153
1992
305
53
Teramura
 
M
Kobayashi
 
S
Hoshino
 
S
Oshimi
 
K
Mizoguchi
 
H
Interleukin-11 enhances human megakaryocytopoiesis in vitro.
Blood
79
1992
327
54
Bree A, Schlerman F, Timony G, McCarthy K, Stoudimire J: Pharmacokinetics and thrombopoietic effects of recombinant human interleukin-11 (rhIL-11) in nonhuman primates and rodents. Blood 78:132a, 1991 (abstr, suppl 1)
55
Gordon
 
MS
McCaskill-Stevens
 
WJ
Battiato
 
LA
Loewy
 
J
Loesch
 
D
Breeden
 
E
Hoffman
 
R
Beach
 
KJ
Kuca
 
B
Kaye
 
J
Sledge
 
GW Jr
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
Blood
87
1996
3615
56
Orazi A, Cooper R, Tong J, Gordon MS, Battiato L, Sledge GW, Kaye J, Hoffman R: Recombinant human interleukin-11 (neumegaTM rhIL-11 growth factor; rhIL-11) has multiple profound effects on human hematopoiesis. Blood 82:369a, 1993 (abstr, suppl 1)
57
Sotiropoulos
 
D
Adamson
 
JW
Mechanism of action of interleukin 11 (IL-11) on in vitro megakaryopoiesis.
Exp Hematol
24
1996
1069
57a
Weich NS, Wang A, Fitzgerald M, Giannotti J, Yetz-Aldape J, Leven RM, Turner KJ: Interleukin-11 receptor expression in megakaryocytes. Blood 88:60a, 1996
58
Ku
 
H
Yonemura
 
Y
Kaushansky
 
K
Ogawa
 
M
Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.
Blood
87
1996
4544
59
Quesniaux
 
VFJ
Clark
 
SC
Turner
 
K
Fagg
 
B
Interleukin-11 stimulates multiple phases of erythropoiesis in vitro.
Blood
80
1992
1218
60
Rodriguez
 
MH
Arnaud
 
S
Blanachet
 
JP
IL-11 directly stimulates murine and human erythroid burst formation in semisolid cultures.
Exp Hematol
23
1995
545
61
de Haan
 
G
Dontje
 
B
Engael
 
C
Loeffler
 
M
Nijhof
 
W
In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis.
Br J Haematol
90
1995
783
62
Cairo
 
MS
Plunkett
 
JM
Nguyen
 
A
Schendel
 
P
Van de ven C
Effect of interleukin-11 with and without granulocyte colony-stimulating factor on in vivo neonatal rat hematopoiesis: Induction of neonatal thrombocytosis by interleukin-11 and synergistic enhancement of neutrophilia by interleukin-11 + granulocyte colony-stimulating factor.
Pediatr Res
34
1993
56
63
Cairo
 
MS
Plunkett
 
JM
Schendel
 
P
Van de ven C
The combined effects of interleukin-11, stem cell factor, and granulocyte colony-stimulating factor on newborn rat hematopoiesis: Significant enhancement of the absolute neutrophil count.
Exp Hematol
22
1994
1118
64
Hirayama
 
F
Clark
 
SC
Ogawa
 
M
Negative regulation of early B lymphopoiesis by interleukin 3 and interleukin 1 alpha.
Proc Natl Acad Sci USA
91
1994
469
65
Hirayama
 
F
Shih
 
J-P
Awgulewitsch
 
A
Warr
 
GW
Clark
 
SC
Ogawa
 
M
Clonal proliferation of murine lymphohemopoietic progenitors in culture.
Proc Natl Acad Sci USA
89
1992
5907
66
Fujimoto
 
K
Lyman
 
SD
Hirayama
 
F
Ogawa
 
M
Isolation and characterization of primitive hematopoietic progenitors of murine fetal liver.
Exp Hematol
24
1996
285
67
Kee
 
BL
Cumano
 
A
Iscove
 
NN
Paige
 
CJ
Stromal cell independent growth of bipotent B cell-macrophage precursors from murine fetal liver.
Int Immunol
6
1994
401
68
Neben
 
T
Donaldson
 
D
Fitz
 
L
Calvetti
 
J
Neben
 
T
Turner
 
K
Hirayama
 
F
Ogawa
 
M
Interleukin-4 (IL-4) in combination with IL-11 or IL-6 reverses the inhibitory effect of IL-3 on early B lymphocyte development.
Exp Hematol
24
1996
783
69
Anderson
 
KC
Morimoto
 
C
Paul
 
SR
Chauhan
 
D
Williams
 
D
Cochran
 
M
Barut
 
BA
Interleukin-11 promotes accessory cell-dependent B-cell differentiation in humans.
Blood
80
1992
2797
70
Yin
 
T
Schendel
 
P
Yu-Chung
 
Y
Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin-11.
J Exp Med
175
1992
211
71
Paul
 
SR
Yang
 
Y-C
Donahue
 
RE
Goldring
 
S
Williams
 
DA
Stromal cell-associated hematopoiesis immortalization and characterization of a primate bone marrow-derived stromal cell line.
Blood
77
1991
1723
72
Thalmeier
 
K
Meissner
 
P
Reisbach
 
G
Hultner
 
L
Mortensen
 
BT
Brechtel
 
A
Oostendorp
 
RA
Dormer
 
P
Constitutive and modulated cytokine expression in two permanent human bone marrow stromal cell lines.
Exp Hematol
24
1996
1
73
Keller
 
DC
Du XX
 
Srour EF
Hoffman
 
R
Williams
 
DA
Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in long term marrow cultures.
Blood
82
1993
1428
74
Krieger
 
MS
Nissen
 
C
Wodnar-Filipowicz
 
A
Stem-cell factor in aplastic anemia: In vitro expression in bone marrow stroma and fibroblast cultures.
Eur J Haematol
54
1995
262
75
Schmitz
 
B
Thiele
 
J
Witte
 
O
Kaufmann
 
R
Wickenhauser
 
C
Fischer
 
R
Influence of cytokines (IL-1a, IL-3, IL-11, GM-CSF ) on megakaryocyte-fibroblast interactions in normal human bone marrow.
Eur J Haematol
55
1995
24
76
Wickenhauser
 
C
Hillienhof
 
A
Jungheim
 
K
Lorenzen
 
J
Ruskowski
 
H
Hansmann
 
ML
Thiele
 
J
Fischer
 
R
Detection and quantification of transforming growth factor beta (TGF-b) and platelet-derived growth factor (PDGF ) release by normal human megakaryocytes.
Leukemia
9
1995
310
77
Mauch
 
P
Lamont
 
C
Neben
 
TY
Quinto
 
C
Goldman
 
SJ
Witsell
 
A
Hematopoietic stem cells in the blood after stem cell factor and interleukin-11 administration: Evidence for different mechanisms of mobilization.
Blood
86
1995
4673
78
Peterson RL, Trepicchio WL, Bozza MM, Wang L, Dorner AJ: G1 growth arrest and reduced proliferation of intestinal eqithelial cells induced by rhIL-11 may mediate protection against mucositis. Blood 86:311a, 1995 (abstr, suppl 1)
79
Du XX
 
Doerschuk CM
Orazi
 
A
Williams
 
DA
A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy.
Blood
83
1994
33
80
Booth
 
C
Potten
 
CS
Effects of IL-11 on the growth of intestinal epithelial cells in vitro.
Cell Prolif
28
1995
581
81
Peterson
 
RL
Bozza
 
MM
Dorner
 
AJ
Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma phosphorylation.
Am J Pathol
149
1996
895
82
Baynes
 
RD
Cook
 
JD
Keith
 
J
Interleukin-11 enhances gastrointestinal absorption of iron in rats.
Br J Haematol
91
1995
230
83
Girasole
 
G
Passeri
 
G
Jilka
 
RL
Manolagas
 
SC
Interleukin-11: A new cytokine critical for osteoclast development.
J Clin Invest
93
1994
1516
84
Hughes
 
FJ
Howells
 
GL
Interleukin-11 inhibits bone formation in vitro.
Calcif Tissue Int
53
1993
362
85
Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N: Modulation of osteoclast differentiation by local factors. Bone 17:87S, 1995 (suppl 2)
86
Romas
 
E
Udagawa
 
N
Zhou
 
H
Tamura
 
T
Saito
 
M
Taga
 
T
Hilton
 
DJ
Suda
 
T
Ng
 
KW
Martin
 
TJ
The role of gp130-mediated signals in osteoclast development: Regulation of interleukin-11 production by osteoblasts and distribution of its receptor in bone marrow cultures.
J Exp Med
183
1996
2581
87
Mehler
 
MF
Rozental
 
R
Dougherty
 
M
Spray
 
DC
Kessler
 
JA
Cytokine regulation of neuronal differentiation of hippocampal progenitor cells.
Nature
362
1993
62
88
Fann
 
M
Patterson
 
PH
Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons.
Proc Natl Acad Sci USA
91
1994
43
89
Rameshwar
 
P
Ganea
 
D
Gascon
 
P
In vitro stimulatory effect of substance P on hematopoiesis.
Blood
81
1993
391
90
Rameshwar
 
P
Ganea
 
D
Gascon
 
P
Induction of IL-3 and granulocyte-macrophage colony-stimulating factor by substance P in bone marrow cells is partially mediated through the release of IL-1 and IL-6.
J Immunol
152
1994
4044
91
Rameshwar
 
P
Gascon
 
P
Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: Potential autoregulatory role for these cytokines in SP receptor expression and induction.
Blood
86
1995
482
92
Hart
 
RP
Shadiack
 
AM
Jonakait
 
GM
Substance P gene expression is regulated by interleukin-1 in cultured sympathetic ganglia.
J Neuroscience Res
29
1991
282
93
Reichlin
 
S
Neuroendocrine-immune interactions.
N Engl J Med
329
1993
1246
94
Weihe
 
E
Nohr
 
D
Michel
 
S
Muller
 
S
Zentel
 
HJ
Fink
 
T
Krekel
 
J
Molecular anatomy of the neuro-immune connection.
Int J Neurosci
59
1991
1
95
Baumann
 
H
Schendel
 
P
Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6.
J Biol Chem
266
1991
20424
96
Fukuda
 
Y
Sassa
 
S
Effect of interleukin-11 on the levels of mRNAs encoding heme oxygenase and haptoglobin in human HepG2 hepatoma cells.
Biochem Biophys Res Commun
193
1993
297
97
Ohsumi
 
J
Miyadai
 
K
Kawashima
 
I
Sakakibara
 
S
Yamaguchi
 
J
Itoh
 
Y
Regulation of lipoprotein lipase synthesis in 3T3-L1 adipocytes by interleukin-11/adipogenesis inhibitory factor.
Biochem Mol Biol Int
32
1994
705
98
Lopez-Valpuesta
 
FJ
Myers
 
RD
Fever produced by interleukin-11 (IL-11) injected into the anterior hypothalamic pre-optic area of the rat is antagonized by indomethacin.
Neuropharmacology
33
1994
989
99
Roeb
 
E
Graeve
 
L
Hoffmann
 
R
Decker
 
K
Edwards
 
DR
Heinrich
 
PR
Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures.
Hepatology
18
1993
1437
99a
Trepicchio WL, Bozza M, Pedneault G, Dorner AJ: Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 157:3627, 1996
99b
Redlich CA, Gao X, Rockwell S, Kelley M, Elias JA: IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 157:1705, 1996
100
Davis
 
S
Aldrich
 
TH
Stahl
 
N
Pan
 
L
Taga
 
T
Kishimoto
 
T
Ip
 
NY
Yancopoulos
 
GD
LIFRβ and gp 130 as heterodimerizing signal transducers of the tripartite CNTF receptor.
Science
260
1993
1805
101
Hilton
 
DJ
Hilton
 
AA
Raicevic
 
A
Rakar
 
S
Harrison-Smith
 
M
Gough
 
NM
Begley
 
CG
Metcalf
 
D
Nicola
 
NA
Willson
 
TA
Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction.
EMBO J
13
1994
4765
102
Nandurkar
 
HH
Hilton
 
D
Nathan
 
P
Wilson
 
T
Nicola
 
N
Begley
 
CG
The human IL-11 receptor require gp130 for signaling: Demonstration by molecular cloning of the receptor.
Oncogene
12
1996
585
103
Cherel
 
M
Sorel
 
M
Lebeau
 
B
Dubois
 
S
Moreau
 
JF
Bataille
 
R
Minvielle
 
S
Jacques
 
Y
Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11.
Blood
86
1995
2534
104
Cherel
 
M
Sorel
 
M
Apiou
 
F
Lebeau
 
B
Dubois
 
S
Jacques
 
Y
Minvielle
 
S
The human interleukin-11 receptor alpha gene (IL11RA): Genomic organization and chromosone mapping.
Genomics
32
1996
49
105
Robb
 
L
Hilton
 
DJ
Willson
 
TA
Begley
 
CG
Structural analysis of the gene encoding the murine interleukin-11 receptor alpha chain and a related locus.
J Biol Chem
271
1996
13754
106
Fourcin
 
M
Chevalier
 
S
Lebrun
 
J-J
Kelly
 
P
Pouplard
 
A
Wijdenes
 
J
Gascan
 
H
Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor.
Eur J Immunol
24
1994
277
107
Nishimoto
 
N
Ogata
 
A
Shima
 
Y
Tani
 
Y
Ogawa
 
H
Nakagawa
 
M
Sugiyama
 
H
Yoshizaki
 
K
Kishimoto
 
T
Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, GP130.
J Exp Med
179
1994
1343
108
Yin
 
T
Taga
 
T
Tsang
 
ML-S
Yasukawa
 
K
Kishimoto
 
T
Yang
 
Y-C
Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.
J Immunol
151
1993
2555
109
Zhang
 
X-G
Gu
 
J-J
Lu
 
Z-Y
Yasukawa
 
K
Yancopoulos
 
GD
Turner
 
K
Shoyab
 
M
Taga
 
T
Kishimoto
 
T
Bataille
 
R
Klein
 
B
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer GP130.
J Exp Med
179
1994
1337
110
Yang
 
Y-C
Yin
 
T
Interleukin-11 and its receptor.
Biofactors
4
1992
15
111
Yin
 
T
Miyazawa
 
K
Yang
 
YC
Characterazation of interlukin-11 receptor and protein tyrosine phosphorylation induced by interluekin-11 in mouse 3T3-L1 cells.
J Biol Chem
267
1992
8347
112
Yin T, Yang Y-C: Interleukin-11 mediated signal transduction pathways: Comparison with those of interleukin-6, in Moody TW (ed): Growth Factors, Peptides, and Receptors. New York, NY, Plenum, 1993, p 323
113
Berger
 
LC
Hawley
 
TS
Lust
 
JS
Goldman
 
SJ
Hawley
 
RG
Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11.
Biochem Biophys Res Commun
202
1994
596
114
Yin
 
T
Yasukawa
 
K
Taga
 
T
Kishimoto
 
T
Yang
 
Y-C
Identification of a 130-kilodalton tyrosine-phosphorylated protein induced by interleukin-11 as JAK2 tyrosine kinase, which associates with gp130 signal transducer.
Exp Hematol
22
1994
467
115
Wang
 
XY
Fuhrer
 
DK
Marshall
 
MS
Yang
 
YC
Interleukin-11 induces complex formation of Grb2, Fyn, and JAK2 in 3T3L1 cells.
J Biol Chem
270
1995
27999
116
Yin
 
T
Yang
 
Y-C
Mitogen-activated protein kinases and ribosomal S6 protein kinases are involved in signaling pathways shared by interleukin-11, interleukin-6, leukemia inhibitory factor, and oncostatin M in mouse 3T3-L1 cells.
J Biol Chem
269
1994
3731
117
Yang
 
YC
Yin
 
T
Interleukin (IL)-11–mediated signal transduction.
Ann NY Acad Sci
762
1995
31
118
Fuhrer
 
DK
Yang
 
YC
Activation of src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3t3-L1 mouse preadipocytes by interleukin-11.
Exp Hematol
24
1996
195
119
Fuhrer
 
DK
Feng
 
GS
Yang
 
YC
Syp associates with gp130 and Janus kinase 2 in response to interleukin-11 in 3T3-L1 mouse preadipocytes.
J Biol Chem
270
1995
24826
120
Siddiqui
 
RA
Yang
 
YC
Interleukin-11 induces phosphatidic acid formation and activates MAP kinase in mouse 3T3-L1 cells.
Cell Signal
7
1995
247
121
Wegenka
 
UM
Lutticken
 
C
Buschmann
 
J
Yuan
 
J
Lottspeich
 
F
Muller-Esterl
 
W
Schindler
 
C
Roeb
 
E
Heinrich
 
PC
Horn
 
F
The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family.
Mol Cell Biol
14
1994
3186
122
Du XX
 
Neben T
Goldman
 
S
Williams
 
DA
Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: Acceleration of recovery of peripheral blood neutrophils and platelets.
Blood
81
1993
27
123
Du XX
 
Keller D
Goldman
 
S
Williams
 
DA
Functional effects of interleukin-11 treatment in vivo following bone marrow transplantation (BMT) and combined modality therapy in mice.
Exp Hematol
20
1992
768
124
Du XX
 
Keller DC
Maze
 
R
Williams
 
DA
Comparative effects of in vivo treatment using interleukin-11 and stem cell factor on reconstitution in mice following bone marrow transplantation.
Blood
82
1993
1016
125
Paul
 
SR
Hayes
 
LL
Palmer
 
R
Morris
 
GE
Neben
 
TY
Loebelenz
 
J
Pedneault
 
G
Brooks
 
J
Blue
 
I
Moore
 
MAS
Muench
 
M
Turner
 
KJ
Schaub
 
R
Goldman
 
SJ
Wood
 
CR
Interleukin-11 expression in donor bone marrow cells improves hematological reconstitution in lethally irradicated recipient mice.
Exp Hematol
22
1994
295
126
Hawley
 
RG
Interleukin-6-type cytokines in myeloproliferative disease.
Ann NY Acad Sci
762
1995
294
127
Hawley
 
RG
Fong
 
AZC
Ngan
 
BY
de Lanux
 
VM
Clark
 
SC
Hawley
 
TS
Progenitor cell hyperplasia with rare development of myeloid leukemia in interleukin 11 bone marrow chimeras.
J Exp Med
178
1993
1175
128
Nash
 
RA
Siedel
 
K
Storb
 
R
Slichter
 
S
Schuening
 
FG
Appelbaum
 
FR
Becker
 
AB
Bolles
 
L
Deeg
 
HJ
Graham
 
T
Hackman
 
RC
Burstein
 
SA
Effects of rhIL-11 on normal dogs and after sublethal radiation.
Exp Hematol
23
1995
389
129
de Haan
 
G
Dontje
 
B
Engel
 
C
Loeffler
 
M
Nijhof
 
W
Prophylactic pretreatmeant of mice with hematopoietic growth factors induces expansion of primitive cell compartments and results in protection against 5-fluorouracil–induced toxicity.
Blood
87
1996
4581
130
Goldman
 
SJ
Preclinical biology of interleukin 11: A multifunctional hematopoietic cytokine with potent thrombopoietic activity.
Stem Cells
13
1995
462
131
Keith
 
JCJ
Albert
 
L
Sonis
 
ST
Pfeiffer
 
CJ
Schaub
 
RG
IL-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestional mucosal biology.
Stem Cells
12
1994
79
132
Maze
 
R
Moritz
 
T
Williams
 
DA
Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11 (IL-11).
Cancer Res
54
1994
4947
133
Sonis S, Muska A, O'Brien J, Van Vugt A, Langer-Safer P, Keith J: Alterations in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer 31B:261, 1995
134
Orazi
 
A
Du XX
 
Yang Z
Kashai
 
M
Williams
 
DA
Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation.
Lab Invest
75
1996
33
135
Potten
 
CS
Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation.
Int J Cancer
62
1995
356
136
Du XX
 
Liu X
Yang
 
Z
Orazi
 
A
Rescorla
 
FJ
Grosfeld
 
JL
Williams
 
DA
The protective effects of interleukin-11 (IL-11) in a murine model of ischemic bowel necrosis.
Am J Physiol
272
1997
545
137
Schindel
 
D
Maze
 
R
Liu
 
Q
Williams
 
DA
Grosfeld
 
J
Interleukin-11 improves survival and reduces bacterial translocation and bone marrow suppression in burned mice.
J Pediatr Surg
32
1997
312
138
Liu
 
Q
Du XX
 
Schindel DT
Yang
 
ZX
Rescorla
 
FJ
Williams
 
DA
Grosfeld
 
JL
Trophic effects of interleukin-11 in rats with experimental short bowel syndrome.
J Pediatr Surg
31
1996
1047
139
Barton
 
BE
Shortall
 
J
Jackson
 
JV
Interleukin-6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model.
Infect Immun
64
1996
714
140
Chang M, Williams A, Ishizawa L, Knoppel A, Van de ven C, Cairo MS: Role of interleukin-11 (IL-11) during experimental group B streptococcal (GBS) sepsis in neonatal rats: Prophylactic use of IL-11 improves survival and enhances platelet recovery. Blood 84:477a, 1994 (abstr, suppl 1)
141
Misra
 
BR
Ferranti
 
TJ
Keith
 
JC Jr
Donnelly
 
LH
Erickson
 
JE
Schaub
 
RG
Recombinant human interleukin-11 prevents hypotension in LPS-treated anesthetized rabbits.
J Endotox Res
3
1996
297
142
Trepicchio
 
WL
Bozza
 
M
Dorner
 
AJ
Recombinant human interleukin-11 attenuates the proinflammatory response through regulation of cytokine gene expression.
Exp Hematol
24
1996
1099
143
Hu
 
JP
Cesano
 
A
Santoli
 
D
Clark
 
SC
Hoang
 
T
Effects of interleukin-11 on the proliferation and cell cycle status of myeloid leukemic cells.
Blood
81
1993
1586
144
Lemoli
 
RM
Fogli
 
M
Fortuna
 
A
Amabile
 
M
Zucchini
 
P
Grande
 
A
Martinelli
 
G
Visani
 
G
Ferrari
 
S
Tura
 
S
Interleukin-11 (IL-11) acts as a synergistic factor for the proliferation of human myeloid leukaemic cells.
Br J Haematol
91
1995
319
145
Kobayashi
 
S
Teramura
 
M
Sugawara
 
I
Oshimi
 
K
Mizoguchi
 
H
Interleukin-11 acts as an autocrine growth factor for human megakaryoblastic cell lines.
Blood
81
1993
889
146
Paul
 
SR
Barut
 
BA
Bennett
 
F
Cochran
 
MA
Anderson
 
KC
Lack of a role of interleukin 11 in the growth of multiple myeloma.
Leuk Res
16
1992
247
147
Burger
 
R
Gramatzki
 
M
Responsiveness of the interleukin (IL)-6-dependent cell line B9 to IL-11.
J Immunol Methods
158
1993
147
148
Lu
 
Z-Y
Zhang
 
X-G
Gu
 
Z-J
Yasukawa
 
K
Amiot
 
M
Etrillard
 
M
Bataille
 
R
Klein
 
B
A highly sensitive quantitative bioassay for human interleukin-11.
J Immunol Methods
173
1994
19
149
Yin
 
T
Yang
 
Y-C
Protein tyrosine phosphorylation and activation of primary response genes by interleukin 11 in B9-TY1 cells.
Cell Growth Diff
4
1993
603
150
Tani
 
Y
Nishimoto
 
N
Ogata
 
A
Shima
 
Y
Yoshizaki
 
K
Kishimoto
 
T
Gp130 in human myeloma/plasmacytoma.
Curr Top Microbiol Immunol
194
1995
229
151
Lu
 
ZY
Gu
 
ZJ
Zhang
 
XG
Wijdenes
 
J
Neddermann
 
P
Rossi
 
JF
Klein
 
B
Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines.
FEBS Lett
377
1995
515
152
Gu
 
ZJ
Wijdenes
 
J
Zhang
 
XG
Hallet
 
MM
Clement
 
C
Klein
 
B
Anti-gp 130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M.
J Immunol Meth
190
1996
21
153
Brosh
 
N
Sternberg
 
J
Honigwachs-Sha'anani
 
J
Lee
 
BC
Shav-Tal
 
Y
Tzehoval
 
E
Shulman
 
LM
Toledo
 
J
Hacham
 
Y
Carmi
 
P
The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11: Identification as a stroma-derived activin A.
J Biol Chem
270
1995
29594
154
Ault KA, Mitchell J, Knowles C, Clendaniel A, Egan A, Loewy J, Garnick MB, Kaye JA: Recombinant human interleukin eleven (neumegaTM rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects. Blood 84:276a, 1994 (abstr, suppl 1)
155
Champlin RE, Mehra R, Kaye JA, Woodin MB, Geisler D, Davis M, Wood J, Andersson B, vanBesien K, Gajewski J, Przepiorka D, Deisseroth AB: Recombinant human interleukin eleven (rhIL-11) following autologous BMT for breast cancer. Blood 84:395a, 1994 (abstr, suppl 1)
156
Cairo
 
MS
Davenport
 
V
Reaman
 
G
Laver
 
J
Kreissman
 
S
Blazar
 
B
Berg
 
S
Patterson
 
F
Kaye
 
J
Accelerated hematopoietic recovery with rhIL-11 following ifosfamide, carboplatin, and etoposide administration in children with solid tumor or lymphoma: Prelimary results of a phase I/II trial.
Exp Hematol
24
1996
1104
157
Isaacs C, Robert N, Loewy J, Kaye JA, Participating Investigators: Neumega® (rhIL-11) prevents platelet transfusions in up to 4 cycles of dose-intense chemotherapy in women with breast cancer. Blood 88:448a, 1996 (abstr, suppl 1)
158
Tepler
 
I
Elias
 
L
Smith
 
W II
Hussein
 
M
Rosen
 
G
Chang
 
AY-C
Moore
 
JO
Gordon
 
MS
Kuca
 
B
Beach
 
KJ
Loewy
 
JW
Garnick
 
MB
Kaye
 
JA
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
Blood
87
1996
3607
159
de Sauvage
 
FJ
Hass
 
PE
Spencer
 
SD
Malloy
 
BE
Gurney
 
AL
Spencer
 
SA
Darbonne
 
WC
Henzel
 
WJ
Wong
 
SC
Kuang
 
W-J
Oles
 
KJ
Hultgren
 
B
Solberg
 
LA Jr
Goeddel
 
DV
Eaton
 
DL
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.
Nature
369
1994
533
160
Bartley
 
TD
Bogenberger
 
J
Hint
 
P
Li
 
Y-S
Lu
 
HS
Martin
 
F
Chang
 
M-S
Samal
 
B
Nichol
 
JL
Swift
 
S
Johnson
 
MJ
Hsu
 
R-Y
Parker
 
VP
Suggs
 
S
Skrine
 
JD
Merewether
 
LA
Clogston
 
C
Hsu
 
E
Hokom
 
MM
Hornkohl
 
A
Choi
 
E
Pangelinan
 
M
Sun
 
Y
Mar
 
V
McNich
 
J
Simonet
 
L
Jacobsen
 
F
Xie
 
C
Shutter
 
J
Chute
 
H
Basu
 
R
Selander
 
L
Trollinger
 
D
Sieu
 
L
Padilla
 
D
Trail
 
G
Elliott
 
G
Izumi
 
R
Covey
 
Tl
Crouse
 
J
Garcia
 
A
Xu
 
W
del Castillo
 
J
Biron
 
J
Cole
 
S
Hu
 
C-T
Pacifici
 
R
Ponting
 
I
Saris
 
C
Wen
 
D
Yung
 
YP
Lin
 
H
Bosselman
 
RA
Identification and cloning of a megakaryocyte growth and deveolopment factor that is a ligand for the cytokine receptor Mpl.
Cell
77
1994
1117
161
Lok
 
S
Kaushansky
 
K
Holly
 
RD
Kuijper
 
JL
Lofton-Day
 
CE
Oort
 
PJ
Grand
 
FJ
Helpel
 
MD
Burkhead
 
SK
Kramer
 
JM
Bell
 
LA
Sprecher
 
CA
Blumberg
 
H
Johnson
 
R
Prunkard
 
D
Ching
 
AFT
Mathewes
 
SL
Balley
 
MC
Forstrom
 
JW
Buddle
 
MM
Osborn
 
SG
Evans
 
SJ
Sheppard
 
PO
Presnell
 
SR
O'Hara
 
PJ
Hagen
 
FS
Roth
 
GJ
Foster
 
DC
Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo.
Nature
369
1994
565
162
Kuter
 
DJ
Beeler
 
DL
Rosenberg
 
RD
The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production.
Proc Natl Acad Sci USA
91
1994
11104
163
Murphy
 
GMJ
Bitting
 
L
Majewska
 
A
Schmidt
 
K
Song
 
Y
Wood
 
CR
Expression of interleukin-11 and its encoding mRNA by glioblastoma cells.
Neurosci Lett
196
1995
153
164
Rier
 
SE
Parsons
 
AK
Becker
 
JL
Altered interleukin-6 production by peritoneal leukocytes from patients with endometriosis.
Fertil Steril
61
1994
294
165
Noble
 
LS
Simpson
 
ER
Johns
 
A
Bulun
 
SE
Aromatase expression in endometriosis.
J Clin Endocrinol Metab
81
1996
174
166
Longley
 
J
Rochester
 
C
Tyrrell
 
L
Einarsson
 
O
Elias
 
J
Interleukin-11 (IL-11) in normal skin and sarcoidosis.
J Invest Dermatol
100
1993
524
167
Paglia
 
D
Oran
 
A
Lu
 
C
Kerbel
 
RS
Sauder
 
DN
McKenzie
 
RC
Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL11 are not coregulated.
J Interferon Cytokin Res
15
1995
455
168
Bank
 
S
Sninsky
 
C
Robinson
 
M
Katz
 
S
Singleton
 
J
Miner
 
P
Safdi
 
M
Galandiuk
 
S
Hanauer
 
S
Varilek
 
G
Sands
 
B
Buchman
 
A
Rogers
 
V
Salzberg
 
B
Cai
 
B
Rogge
 
H
Schwertschlag
 
U
Safety and activity evaluation of rhIL-11 in subjects with active Crohn's disease.
Shock
7
1997
520
Sign in via your Institution